利伐沙班在儿童血栓栓塞性疾病中的研究进展  

Research Progress of Rivaroxaban in Children with Thromboembolic Diseases

作　　者：侯微 冯鑫[1] 张金红[1] 殷述刚[2] 房德敏[1] HOU Wei;FENG Xin;ZHANG Jin-hong;YIN Shu-gang;FANG De-min(Department of Pharmacy,Tianjin Hospital,Tianjin 300211,China;Vascular Surgery,Tianjin Hospital,Tianjin 300211,China)

机构地区：[1]天津市天津医院药学部,天津300211 [2]天津市天津医院血管外科,天津300211

出　　处：《中国药学杂志》2021年第4期270-275,共6页Chinese Pharmaceutical Journal

摘　　要：Xa因子抑制剂利伐沙班作为一种安全有效的口服抗凝剂,具有明确的药学特性,是当前多种成人血栓栓塞性疾病(thromboembolic disease, TED)的一线治疗药物。随着儿童抗凝用药的需求日趋增多,利伐沙班在儿科领域显示出巨大的潜力。笔者通过查阅近年来国内外相关指南、文献,总结0~18岁儿童TED的流行病学特点、凝血系统特点,综述利伐沙班在此类特殊人群中的药学特性、临床疗效及安全性相关研究,以期为儿科临床合理应用利伐沙班提供依据。Rivaroxaban, the first oral factor Xa inhibitor, is a safe and effective oral anticoagulant with definite pharmaceutical properties. It is the first-line treatment of various thromboembolic disease(TED) in adults. With the increasing demand for anticoagulants in children, rivaroxaban shows great potential in the field of pediatrics. This article collected the latest guidelines and literatures related to rivaroxaban in children aged 0-18, and summarized the epidemiological characteristics of TED, the characteristics of coagulation system, the research in pharmaceutical characteristics and clinical efficacy and safety, so as to provide a basis for the rational use of rivaroxaban in pediatrics.

关 键 词：利伐沙班 儿童 血栓栓塞性疾病 

分 类 号：R969.3[医药卫生—药理学]